Company / Capital Expenditures
ResMed Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$89.9M
FY2025
5-year range
$89.9M / $134.8M
FY2021-FY2025
Trend
-9.6%
vs FY2024
Sector context
#63 of 145
Health Care
What the data says
At $90M, ResMed's capital expenditures ranks #63 of 145 in the Health Care sector. Capital Expenditures has declined for 3 consecutive years, from $135M in FY2022 to $90M in FY2025.
Based on SEC 10-K filings.
$90M in FY2025 with a 5-year CAGR of -1.2%.
Declined from $120M to $90M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -12.7%
- 5-Year CAGR
- -1.2%
- 10-Year CAGR
- -
Sector benchmark
#63 of 145 in Health CareTop 43% of 145This company $89.9M Sector average $268.6M
▼
-66.5% below sector average
Key checks
Key Insights
- ResMed's capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -1.2%, indicating a declining trend.
- In FY2025, capital expenditures decreased 9.6% year-over-year.
- Ranks #63 out of 145 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.9M | -9.6% |
| FY2024 | $99.5M | -16.9% |
| FY2023 | $119.7M | -11.2% |
| FY2022 | $134.8M | +31.3% |
| FY2021 | $102.7M | +7.7% |
| FY2020 | $95.3M | +38.7% |
| FY2019 | $68.7M | +9.8% |
| FY2018 | $62.6M | +0.6% |
| FY2017 | $62.2M | +6.3% |
| FY2016 | $58.5M | -6.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026